SCHEMBL23530615

SCHEMBL23530615

Cc1cn2cc(CN)nc2cc1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.35
ALDH1A1 P00352 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
POLB P06746 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SMN1; SMN2 Q16637 4/20 0.34
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
CACNA1H O95180 1/20 0.33
NSD2 O96028 1/20 0.32
HSD17B10 Q99714 3/20 0.32
HPGD P15428 2/20 0.32
RXFP1 Q9HBX9 1/20 0.32
NOTUM Q6P988 1/20 0.31
MAPT P10636 2/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23530635 0.84 MCHR1 (0.41) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL23530804 0.84 KDM4E (0.35) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL23530787 0.77 KDM4E (0.42) KDM4EALDH1A1TDP1POLBL3MBTL1
Hydrochloric Acid SCHEMBL31312583 0.74 KDM4E (0.61) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL22529080 0.72 KDM4E (0.63) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL23530832 0.72 NOTUM (0.43) KDM4EALDH1A1TDP1POLBL3MBTL1
Hydrochloric Acid SCHEMBL22499393 0.71 NPC1 (0.49) KDM4EALDH1A1POLBL3MBTL1SMN1; SMN2
SCHEMBL22499097 0.71 KDM4E (0.50) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL23530863 0.69 NPC1 (0.50) KDM4EALDH1A1POLBL3MBTL1SMN1; SMN2
SCHEMBL23530991 0.69 KDM4E (0.62) KDM4EALDH1A1POLBL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473303-B2 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use Carrick Therapeutics Limited (IE) 2025-11-18 US disclosed
CN-114929708-B 4- [ [ (7-Aminopyrazolo [1,5-a ] pyrimidin-5-yl) amino ] methyl ] piperidin-3-ol compounds and their therapeutic uses 卡里克治疗有限公司 2025-02-18 CN disclosed
US-20230144197-A1 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2023-05-11 US disclosed
US-20230144197-A1 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2023-05-11 US disclosed
US-20230144197-A1 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2023-05-11 US disclosed
CN-114929708-A 4- [ [ (7-aminopyrazolo [1,5-A ] pyrimidin-5-yl) amino ] methyl ] piperidin-3-ol compounds and their therapeutic use 卡里克治疗有限公司 2022-08-19 CN disclosed
WO-2021122745-A1 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230144197-A1 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE CDK1, CDK3, CDK2 KDM4E 1443/4885ALDH1A1 4481/4885TDP1 440/4885
US-12473303-B2 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use CDK3, CDK1, CDK2 KDM4E 1437/4885ALDH1A1 4449/4885TDP1 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.